Talk:Immunocore

Latest comment: 8 years ago by MaynardClark in topic ImmTAV

Suggested Addition

edit

Suggested addition to article: "In June 2013, Immunocore signed a deal with Genentech, worth between $10 and $30 million per programme, for the discovery and development of cancer treatments Cite error: There are <ref> tags on this page without content in them (see the help page). http://www.fiercebiotech.com/press-releases/immunocore-and-genentech-enter-strategic-alliance-develop-immtacs-multiple" Cite error: There are <ref> tags on this page without content in them (see the help page). http://www.independent.co.uk/news/science/exclusive-cancer--a-cure-just-got-closer-thanks-to-a-tiny-british-company--and-the-result-could-change-lives-of-millions-8707590.html Pool59 (talk) 12:48, 22 July 2013 (UTC)Reply

  Done I changed the source b/c there was very little info about Genentech in the Independent piece and a company press release is no the best source. NickCT (talk) 19:48, 23 July 2013 (UTC)Reply

Immunocore’s novel bispecific biologics are based on precision-engineered, soluble T cell receptors, known as ImmTACs (Immune mobilising mTCR Against Cancer). Cite error: There are <ref> tags on this page without content in them (see the help page). http://www.nature.com/nm/journal/v18/n6/full/nm.2764.html Cite error: There are <ref> tags on this page without content in them (see the help page). http://www.landesbioscience.com/journals/oncoimmunology/article/22891/ Pool59 (talk) 14:35, 2 August 2013 (UTC)Reply

  Done I rephrased significantly and added a little background on T-cell receptors. NickCT (talk) 19:27, 5 August 2013 (UTC)Reply

Bold Changes

edit

I am going to be bold and make some changes to the article which I believe will improve it. First of all, the history should come before the discussion of the background scientific information explaining what the company does. So I am just moving history to the top. After I do that, I will see what other improvements can be made.Feelingfancyfree (talk) 09:04, 29 April 2015 (UTC)Reply

ImmTAV

edit

Professor Lucy Dorrell and her team at the University of Oxford worked with Immunocore Ltd - a UK biotechnology company based in Oxfordshire - to investigate the potency of novel engineered immune-mobilising T cell receptors-based drugs ('ImmTAVs'), designed to clear HIV-infected cells.

I suggest that we consider including this revolutionary development in the article.[1][2][3] They are being used also for zika infection. MaynardClark (talk) 21:53, 22 July 2016 (UTC)Reply

References